Product Description
Mechanisms of Action: KLK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BCX-17725](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Netherton Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BCX17725-101 | P1 |
Not yet recruiting |
Netherton Syndrome |
2025-07-01 |